Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 354

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 354
---
 person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. Notice to Prospective Investors in Canada The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 ProspectusExemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 RegistrationRequirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. 237

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor. Pursuant to section 3A.3 of National Instrument 33-105 UnderwritingConflicts (NI 33-105), theunderwriters are not required to comply with the disclosure requirements of NI 33-105 regardingunderwriter conflicts of interest in connection with this offering. Notice to Prospective Investors in Australia This prospectus:

| A. | does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 
 (Cth), or the Corporations Act;                                                                           |

| B. | has not been, and will not be, lodged with the Australian Securities and Investments Commission, or ASIC, as a                                                                               
 disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and |

| C. | may only be provided in Australia to select investors who are able to demonstrate that they fall within one or 
 more of the categories of investors, available under section 708 of the Corporations Act, or Exempt Investors. |

The shares of common stock may not